ETF model portfolios designed for real investor needs. Discover →
Invesco Dynamic Biotechnology & Genome ETF
PBE performance and flow charts
Performance
Flows
Historic performance and flows
Data as of April 24, 2026| 1M | 3M | YTD | 1Y | 3Y | 5Y | |
|---|---|---|---|---|---|---|
| Perf. | +4.27% | -3.98% | -2.66% | +32.11% | +28.24% | +3.38% |
| Flows | +$2M | -$6M | -$2M | -$30M | -$58M | -$43M |
Characteristics
The Invesco Dynamic Biotechnology & Genome ETF is built to track the Dynamic Biotech & Genome Intellidex TR Index - USD. This ETF provides physical exposure - by owning its shares you earn the return of the securities composing the index (as the ETF holds them directly). This share class generates a stream of income by distributing dividends.
| Management strategy | Passive |
| Strategy | Long Only |
| Provider | Invesco |
| N° of holdings | 30 |
| Replication method | Direct (Physical) |
| Asset class | Equity |
| Dividend policy | Distributing |
Trailing 12m distribution yield | Join for free |
| Inception date | June 23, 2005 |
| ESG | No |
More data and info about PBE on Trackinsight
Exposure
Data as of March 31, 2026Diversification
Total weight of top 15 holdings out of 30
Top 15 Holdings
Sectors
Countries
Similar ETFs
Trading data
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Volatility | +19.57% | +19.83% | +20.15% | +22.54% |
Max drawdown | -9.36% | -11.70% | -22.21% | -34.74% |
Max drawdown duration | 75d | 107d | 324d | 1540d |
Time to recover | N/A | N/A | 177d | 1256d |
Replication quality
Data as of March 31, 2026Create an account to view replication metrics
1 year cumulative return difference | |
|---|---|
| Best | Join for free |
| Worst | Join for free |
| daily return difference | |
|---|---|
| Average | Join for free |
| Worst | Join for free |
What type of ETF is PBE?
PBE is a Passive ETF that provides exposure to Equity assets. It is managed by Invesco.
What index does PBE track?
PBE tracks the Dynamic Biotech & Genome Intellidex TR Index - USD, aiming to replicate its performance through full replication.
What does PBE invest in?
This ETF provides exposure to Equally Weighted US Equities. It is part of the segment: BioTech & Genomics.
What is the expense ratio of PBE?
The total expense ratio (TER) of PBE is 0.58%, representing the annual fee charged by the fund manager.
When was PBE launched?
PBE was launched on June 23, 2005, marking its entry into the ETF market.
Who is the issuer of PBE?
PBE is issued by Invesco.
What is the AUM of PBE?
As of April 24, 2026, PBE manages $249.88 M, reflecting the total assets held in the fund.
How has PBE performed recently?
As of April 24, 2026, PBE delivered a return of 4.27% over the past month (1M performance), -3.98% over the past three months (3M), and -2.66% year-to-date (YTD).
What are the recent fund flows for PBE?
As of April 24, 2026, PBE has seen net flows of +$2M in the past month (1M flow) and -$2M year-to-date (YTD).
Does PBE pay dividends?
As of April 24, 2026, PBE has a trailing 12-month distribution yield of 1.09%.
How many holdings are in PBE
As of March 31, 2026, PBE holds 30 securities in its portfolio. This level of diversification can influence the fund’s risk profile and exposure to individual assets.
How diversified is PBE?
As of March 31, 2026, PBE holds 30 securities, with 63.66% of its assets concentrated in its top 15 holdings.
What are the top holdings of PBE?
As of March 31, 2026, PBE holds a portfolio of 30 underlyings, with its largest positions including UTD THERAPEUT, ILLUMINA and REGENERON PHARMACEUTICALS. These top holdings play a significant role in shaping the fund’s performance and exposure.
What countries or regions does PBE invest in?
As of March 31, 2026, PBE has its largest geographic exposures in USA.
What sectors or themes does PBE focus on?
As of March 31, 2026, PBE is primarily exposed to Health Care.
Advantages of ETFs over Mutual Funds1/6
Lower Costs
In this guide, we'll explore the advantages of ETFs over mutual funds, giving you valuable insights into why ETFs have gained significant popularity among investors like yourself.
Leveraged ETFs: Unlocking the Potential for Amplified Returns1/6
Understanding Leveraged ETFs
Explore leveraged ETFs: potential for amplified returns & risks. 5 ETFs to consider across equities, commodities & fixed income.
What is a Leveraged ETF?1/6
Introducing Leveraged and Inverse ETFs
In this guide, we'll dive into the world of leveraged ETFs, exploring their definition, mechanics, potential risks, and rewards.
Recent educational content
Asset TV
The ETF Show - Investors Can Fight Healthcare Inflation with Newly Launched ETFs
Adam Schenck, Principal and Managing Director of Fund Services at Milliman joined The ETF Show to discuss Milliman's first ETFs designed to hedge against rising healthcare inflation.
ETF Trends
ETF Industry KPIs April 20, 2026
The ETF Industry saw 14 New Launches, 1 Ticker Change and 16 closures last week.
Asset TV
The ETF Show - Investors Run to Cash Alternatives as Markets Remain Volatile
Jason England, Portfolio Manager and Fixed Income Strategist from Simplify joined The ETF Show to discuss investor allocations to fixed income as markets continue on their rollercoaster ride.
ETF Trends
ETF Industry KPIs March 30, 2026
The ETF Industry saw 33 New Launches, 1 Ticker Change and 9 closures last week.
Browse all educational columns
Active Trader Report: Use of Leveraged & Inverse ETFs Way Up
Direxion partnered with Compound Insights and Vanda to explore what’s driving the evolution of active trading — and how active traders are using leveraged and inverse funds across equities, single stocks, commodities, and volatility.
